Serum-Urine Matched Metabolomics for Predicting Progression of Henoch-Schonlein Purpura Nephritis.
Henoch-Schonlein purpura nephritis
choline and cis-vaccenic acid
differential diagnosis
nephrotic proteinuria
serum-urine matched metabolomics
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
01
2021
accepted:
15
04
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
epublish
Résumé
Henoch-Schonlein purpura nephritis (HSPN) is a common glomerulonephritis secondary to Henoch-Schonlein purpura (HSP) that affects systemic metabolism. Currently, there is a rarity of biomarkers to predict the progression of HSPN. This work sought to screen metabolic markers to predict the progression of HSPN via serum-urine matched metabolomics. A total of 90 HSPN patients were enrolled, including 46 HSPN (+) patients with severe kidney damage (persistent proteinuria >0.3 g/day) and 44 HSPN (-) patients without obvious symptoms (proteinuria < 0.3 g/day). Untargeted metabolomics was determined by liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-Q/TOF-MS). A total of 38 and 50 differential metabolites were, respectively, identified in serum and urine from the comparison between HSPN (+) and HSPN (-) patients. Altered metabolic pathways in HSPN (+) mainly included glycerophospholipid metabolism, pyruvate metabolism, and citrate cycle. A panel of choline and
Identifiants
pubmed: 34055834
doi: 10.3389/fmed.2021.657073
pmc: PMC8149729
doi:
Types de publication
Journal Article
Langues
eng
Pagination
657073Informations de copyright
Copyright © 2021 Zhang, Lai, Cai, Wang, Ma, Qi, Xue and Huang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Histol Histopathol. 2011 Dec;26(12):1599-610
pubmed: 21972098
Nat Rev Mol Cell Biol. 2016 Jul;17(7):451-9
pubmed: 26979502
Kidney Int. 1993 Feb;43(2):448-53
pubmed: 8441242
J Urol. 2008 Nov;180(5):2218-25
pubmed: 18804795
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):342-353
pubmed: 30733224
Autoimmun Rev. 2015 Jul;14(7):579-85
pubmed: 25688001
Acta Derm Venereol. 2017 Nov 15;97(10):1160-1166
pubmed: 28654132
Nutrients. 2019 Mar 28;11(4):
pubmed: 30925738
Kidney Int. 1996 Jun;49(6):1684-5
pubmed: 8743477
Transl Oncol. 2020 Feb;13(2):177-185
pubmed: 31865180
Am J Physiol Renal Physiol. 2013 Jun 1;304(11):F1317-24
pubmed: 23467425
Lipids Health Dis. 2019 Jul 8;18(1):151
pubmed: 31286991
Clin Proteomics. 2020 Mar 12;17:10
pubmed: 32190014
Life Sci. 2020 Oct 1;258:118160
pubmed: 32730837
Biomedicines. 2020 Jul 17;8(7):
pubmed: 32708997
J Biol Chem. 2004 Oct 29;279(44):45855-64
pubmed: 15302887
Circulation. 2020 Jun 23;141(25):2095-2105
pubmed: 32164457
J Pharm Biomed Anal. 2018 Feb 5;149:1-8
pubmed: 29100025
Nutrients. 2019 Jul 20;11(7):
pubmed: 31330812
Int Immunopharmacol. 2020 Apr;81:106229
pubmed: 32014710
Circ Res. 2015 Jan 30;116(3):448-55
pubmed: 25599331
Am J Physiol Renal Physiol. 2003 Sep;285(3):F413-22
pubmed: 12759229
Prostaglandins Leukot Essent Fatty Acids. 2012 Apr;86(4-5):175-82
pubmed: 22417701
Clin Rheumatol. 2018 May;37(5):1319-1324
pubmed: 29330742
Clin J Am Soc Nephrol. 2011 Mar;6(3):679-89
pubmed: 21393485
Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1726-1727
pubmed: 28971981